Anzeige
Mehr »
Sonntag, 27.07.2025 - Börsentäglich über 12.000 News

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2DXZH | ISIN: FR0013280286 | Ticker-Symbol: EYWN
Tradegate
25.07.25 | 15:06
124,20 Euro
-1,27 % -1,60
1-Jahres-Chart
BIOMERIEUX Chart 1 Jahr
5-Tage-Chart
BIOMERIEUX 5-Tage-Chart
RealtimeGeldBriefZeit
125,10126,2026.07.
125,20126,4025.07.

Aktuelle News zur BIOMERIEUX Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
16.06.BIOMERIEUX: bioMérieux strengthens its next-generation sequencing capabilities with the acquisition of Day Zero Diagnostics solutions and technologies7
09.06.Dividendenbekanntmachungen (09.06.2025)6.917 Unternehmen  ISIN-Code  Dividende (Währung)  Dividende (EUR)  ALLSTATE CORPORATION  US0200021014  1 USD  0,8776 EUR  ALPHABET INC CL A  US02079K3059  0,21 USD  0,1842 EUR  ALPHABET INC CL C  US02079K1079  0...
► Artikel lesen
03.06.BIOMERIEUX: bioMérieux launches cutting-edge equine infectious respiratory disease testing3
22.05.GXO Logistics: GXO extends longstanding partnership with bioMérieux363PARIS, France, May 22, 2025 (GLOBE NEWSWIRE) -- GXO Logistics, Inc. (NYSE: GXO), the world's largest pure-play contract logistics provider, today announced a long-term contract renewal and extension...
► Artikel lesen
07.05.RBC Capital cuts BioMerieux stock rating on FX, tariff concerns3
22.04.BIOMERIEUX: WATCHFIRE by bioMérieux: a PCR test to detect viruses and bacteria in wastewater and respond to potential infectious disease outbreaks3
BIOMERIEUX Aktie jetzt für 0€ handeln
17.04.BIOMERIEUX: bioMérieux - First-Quarter 2025 Business Review4
07.04.BIOMERIEUX: bioMérieux obtains CE-marking for LUMED APSS, a cutting-edge software solution to aid medical decision-making in Antimicrobial Stewardship3
24.03.BIOMERIEUX: Release of the Universal Registration Document including the Annual Financial Report as of December 31, 20242
18.03.bioMérieux receives FDA 510(k) Clearance for its VITEK COMPACT PRO, a new ID/AST system to fight against antimicrobial resistance552MARCY L'ÉTOILE, France, March 18, 2025 /PRNewswire/ -- bioMérieux, a world leader in the field of in vitro diagnostics, announces the U.S. Food and Drug Administration...
► Artikel lesen
07.03.Biomerieux projects strong 2025 growth as molecular sales outperform expectations7
07.03.BIOMERIEUX: bioMérieux - 2024 Financial Results5
03.03.QIAGEN Files Patent Complaint Against BioMérieux To Protect QuantiFERON Technology938PARIS (dpa-AFX) - QIAGEN N.V. (QGEN) announced that it has filed a complaint against bioMrieux S.A. for patent infringement, reinforcing its commitment to protecting the scientific advancements...
► Artikel lesen
25.02.bioMérieux Receives Health Canada Approval for the BIOFIRE SPOTFIRE Respiratory/Sore Throat (R/ST) Panel3
13.02.BIOMERIEUX: bioMérieux launches GENE-UP® TYPER, an innovative diagnostic solution for food industries to rapidly analyze the root cause of contamination of Listeria monocytogenes2
11.02.BIOMERIEUX: bioMérieux receives U.S. FDA clearance for the new version of its molecular test targeting causes of gastroenteritis, BIOFIRE® FILMARRAY® Gastrointestinal (GI) Panel Mid4
07.11.24Research and Markets: Europe Companion Diagnostics Market Analysis and Forecast, 2023-2033 with Competitive Analysis of Key Players - bioMerieux, F. Hoffmann-La Roche, ICON, and QIAGEN - ResearchAndMarkets.com972The "Europe Companion Diagnostics Market: Focus on Application, End User, Technology, and Country Analysis and Forecast, 2023-2033" report has been added to ResearchAndMarkets.com's offering. The...
► Artikel lesen
17 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1